TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4921703

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside and daunorubicin with L-asparaginase (N=10)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cytosine arabinoside and daunorubicin without L-asparaginase (N=13)
Number of subjects: 23
Study: 30944936

Group type: EXPERIMENTAL
Intervention: Ajust tape
Number of subjects: 100

Group type: COMPARATOR
Intervention: TVT-O tape
Number of subjects: 100
Study: 28840662

Group type: EXPERIMENTAL
Intervention: Extended-duration betrixaban
Number of subjects: 7513

Group type: COMPARATOR
Intervention: Standard-duration enoxaparin
Number of subjects: 7513
Study: 26646031

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids plus inositol
Number of subjects: 24
Study: 22831953

Group type: EXPERIMENTAL
Intervention: Low-fat diet only
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Physical activity only
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Diet plus physical activity
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control
Number of subjects: 276
Study: 21467560

Group type: EXPERIMENTAL
Intervention: 20 mL of 0.25% bupivacaine (TAP group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 40
Study: 19538204

Group type: EXPERIMENTAL
Intervention: Adjustment of AED treatment (53 patients), either reduction of dose or switch of AED
Number of subjects: 111

Group type: COMPARATOR
Intervention: Continuation of treatment unchanged (58 control patients)
Number of subjects: 111
Study: 16776753

Group type: EXPERIMENTAL
Intervention: Moxonidine 0.2 mg twice daily for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin 500 mg twice daily for 16 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatments (Moxonidine and Metformin)
Number of subjects: 0
Study: 15468561

Group type: EXPERIMENTAL
Intervention: Algorithm of respiratory management (RM)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Routine RM algorithm (Control)
Number of subjects: 42
Study: 15178175

Group type: EXPERIMENTAL
Intervention: Cerebellar patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 10752919

Group type: EXPERIMENTAL
Intervention: Salmeterol powder 50 microg twice daily via Diskus
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Salmeterol aerosol 42 microg twice daily via MDI
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study: 8931532

Group type: EXPERIMENTAL
Intervention: Digital testing of the bulbocavernous muscles, the sphincter ani externus, the puborectal muscles
Number of subjects: 39
Study: 1532616

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Felodipine plus metoprolol
Number of subjects: 76
Study: 4029242

Group type: EXPERIMENTAL
Intervention: Oral prajmaline bitartrate
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 3144333

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Relaxation and imagery training
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (talking about themselves)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Women aged 55 and over
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Leeds general scales for depression and anxiety
Number of subjects: 154
Study: 31712321

Group type: EXPERIMENTAL
Intervention: High-Fat Overfeeding (HFOF) (60% fat, 20% carbohydrate)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Standard Overfeeding (STOF) (50% carbohydrate, 30% fat)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: High-Carbohydrate Overfeeding (HCOF) (75% carbohydrate, 5% fat)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 79

Group type: COMPARATOR
Intervention: Energy Balance (EBL) (50% carbohydrate, 30% fat)
Number of subjects: 79
Study: 31415655

Group type: EXPERIMENTAL
Intervention: YH1
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 28843255

Group type: EXPERIMENTAL
Intervention: Multi-component intervention including information delivery, modeling, and persuasion through video presentation, group discussion, role playing, and postcards.
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 480
Study: 25967990

Group type: EXPERIMENTAL
Intervention: Holistic needs assessment (HNA) prior to consultation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care - routine consultation between the patient and clinician
Number of subjects: 0
Study: 23629717

Group type: EXPERIMENTAL
Intervention: Voriconazole (VCZ)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: N-oxide voriconazole (N-oxide VCZ)
Number of subjects: 10
Study: 21737654

Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Overall costs of percutaneous ethanol injection
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Overall costs of radiofrequency ablation
Number of subjects: 285
Study: 19858981

Group type: EXPERIMENTAL
Intervention: Group 1: Daily showering and brushing pin sites with soap and a soft toothbrush after initial 15 days of care (310 pin sites)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Group 2: Daily showering and cleaning crusts with sterile gauze impregnated with 10% polyvinylpyrrolidone iodine after initial 15 days of care (300 pin sites)
Number of subjects: 39
Study: 16697307

Group type: EXPERIMENTAL
Intervention: Biventricular (BV) pacing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional right ventricular (RV) pacing
Number of subjects: 30
Study: 15177822

Group type: EXPERIMENTAL
Intervention: Corticobasal degeneration (CBD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy adults (control group)
Number of subjects: 16
Study: 11878522

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 321

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 321
Study: 9777474

Group type: EXPERIMENTAL
Intervention: California Verbal Learning Test (CVLT) indices for detecting malingered head injury
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diagnostic cutoff scores for Recognition Discriminability and Recognition Hits
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Indices based on subtle principles of learning theory
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Exposure to a simple instructional set
Number of subjects: 90
Study: 7530469

Group type: EXPERIMENTAL
Intervention: Pre-operative radiotherapy (3 x 5 Gy over 5 days within 2 days of operation) followed by surgery
Number of subjects: 468

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 468
Study: 3046816

Group type: EXPERIMENTAL
Intervention: Caffeine, 300 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg with caffeine pretreatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nifedipine, 10 mg with placebo pretreatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine pretreatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 10
Study: 30316010

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy (3 mg/kg every 2 weeks)
Number of subjects: 109
Study: 28609401

Group type: EXPERIMENTAL
Intervention: MISC (mediational intervention for sensitizing caregivers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutrition curriculum (control)
Number of subjects: 0
Study: 25357214

Group type: EXPERIMENTAL
Intervention: MAP target of 85 mmHg (HLH group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MAP target of 65 mmHg (LHL group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion (LHL group)
Number of subjects: 16
Study: 22985213

Group type: EXPERIMENTAL
Intervention: Liraglutide (0.6 mg)
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg)
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg)
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 1091

Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 1091
Study: 22069291

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study: 19140039

Group type: EXPERIMENTAL
Intervention: Salt capsules
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 46
Study: 16169629

Group type: EXPERIMENTAL
Intervention: Green tea consumption
Number of subjects: 0
Study: 15282425

Group type: EXPERIMENTAL
Intervention: 5 French guiding catheters
Number of subjects: 216

Group type: COMPARATOR
Intervention: 6 French guiding catheters
Number of subjects: 216
Study: 11694150

Group type: EXPERIMENTAL
Intervention: Purified poloxamer 188
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Purified poloxamer 188 in children aged 15 years or younger
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Purified poloxamer 188 in patients receiving hydroxyurea
Number of subjects: 255
Study: 9030834

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice per day)
Number of subjects: 9
Study: 7910732

Group type: EXPERIMENTAL
Intervention: Cognitive therapy followed by in vivo exposure
Number of subjects: 24

Group type: COMPARATOR
Intervention: Associative therapy followed by in vivo exposure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cognitive therapy alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Associative therapy alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cognitive therapy combined with in vivo exposure
Number of subjects: 24

Group type: COMPARATOR
Intervention: Associative therapy combined with in vivo exposure
Number of subjects: 24
Study: 3112261

Group type: EXPERIMENTAL
Intervention: Diflunisal in combination with bupivacaine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Paracetamol with codeine and lignocaine
Number of subjects: 16
Study: 30938127

Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Gluten-containing diet
Number of subjects: 16
Study: 28163108

Group type: EXPERIMENTAL
Intervention: Protein-enriched milk (2×20g protein/d)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Isocaloric carbohydrate drink
Number of subjects: 31
Study: 26078236

Group type: EXPERIMENTAL
Intervention: Fast track surgery model based on preoperative nutritional risk screening (NRS 2002)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional method (control group)
Number of subjects: 180
Study: 23943730

Group type: EXPERIMENTAL
Intervention: Amitriptyline with pindolol
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 62

Group type: COMPARATOR
Intervention: Surrogate placebo (loratadine)
Number of subjects: 62
Study: 21879200

Group type: EXPERIMENTAL
Intervention: Iloprost infusion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 19277420

Group type: EXPERIMENTAL
Intervention: Desmoteplase 180 microg/kg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Desmoteplase 250 microg/kg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Desmoteplase (higher doses)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Alteplase 100 mg
Number of subjects: 34
Study: 17685678

Group type: EXPERIMENTAL
Intervention: Depth jumps from 46 cm
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Depth jumps from 61 cm
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pike jump
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tuck jump
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Single‐leg jump
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Countermovement jump
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Squat jump
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Squat jump holding dumbbells equal to 30% of 1 RM
Number of subjects: 6

Group type: COMPARATOR
Intervention: All exercises
Number of subjects: 6
Study: 15012646

Group type: EXPERIMENTAL
Intervention: Immediate PLA injections (weeks 0, 2, and 4)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Delayed PLA injections (weeks 12, 14, and 16)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both immediate and delayed PLA injections
Number of subjects: 30
Study: 11376522

Group type: EXPERIMENTAL
Intervention: Evidence-Based Medicine
Number of subjects: 0
Study: 9604056

Group type: EXPERIMENTAL
Intervention: Mobile dual-energy X-ray absorptiometry (DXA) unit for osteoporosis screening
Number of subjects: 1774

Group type: EXPERIMENTAL
Intervention: Mobile DXA unit
Number of subjects: 1774
Study: 8243375

Group type: EXPERIMENTAL
Intervention: Felbamate (FBM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dosage valproate (VPA)
Number of subjects: 0
Study: 3038003

Group type: EXPERIMENTAL
Intervention: Sultamicillin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cloxacillin
Number of subjects: 52
Study: 31910302

Group type: EXPERIMENTAL
Intervention: Transcutaneous functional electrical stimulation for 8 weeks (5 days a week)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Transcutaneous functional electrical stimulation for 4 weeks of ineffective stimulation followed by 4 weeks of effective training
Number of subjects: 14
Study: 30475965

Group type: EXPERIMENTAL
Intervention: Observational studies (men)
Number of subjects: 7271

Group type: EXPERIMENTAL
Intervention: Observational studies (women)
Number of subjects: 7271

Group type: EXPERIMENTAL
Intervention: Intervention studies (men)
Number of subjects: 7271

Group type: EXPERIMENTAL
Intervention: Intervention studies (women)
Number of subjects: 7271

Group type: EXPERIMENTAL
Intervention: All studies
Number of subjects: 7271
Study: 25790724

Group type: COMPARATOR
Intervention: Leucine-enriched whey protein (150 kcal)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Leucine-enriched whey protein (320 kcal)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-caloric products
Number of subjects: 12
Study: 24892221

Group type: EXPERIMENTAL
Intervention: Hydrokinesytherapy (3 times/week) in addition to conventional physical therapy (3 times/week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional physical therapy (6 times/week)
Number of subjects: 0
Study: 22364561

Group type: EXPERIMENTAL
Intervention: Home-based modified constraint-induced movement therapy plus trunk restraints (3 hours/day, 5 days/week for 2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home-based modified constraint-induced movement therapy (3 hours/day, 5 days/week for 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based modified constraint-induced movement therapy plus trunk restraints
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home-based modified constraint-induced movement therapy
Number of subjects: 0
Study: 20164787

Group type: EXPERIMENTAL
Intervention: Candesartan plus bepridil (n = 52)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Carvedilol plus bepridil (n = 51)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Bepridil alone (n = 50)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 153

Group type: COMPARATOR
Intervention: Bepridil group vs. Candesartan group
Number of subjects: 153
Study: 18549462

Group type: EXPERIMENTAL
Intervention: Chewing-gum
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (no chewing-gum)
Number of subjects: 93
Study: 16098314

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE) assessment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Follow-up TEE examinations
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Anticoagulant and/or antiplatelet treatment
Number of subjects: 56
Study: 12393567

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (Cy)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Antithymocyte globulin (ATG)
Number of subjects: 21
Study: 10343421

Group type: EXPERIMENTAL
Intervention: Brief advice from a GP plus extended counselling and follow‐up from a trained practice nurse
Number of subjects: 497

Group type: COMPARATOR
Intervention: Brief advice from a GP alone
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Extended counselling
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 497
Study: 7551845

Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 g intravenously 20 min before TPB)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam (4.5 g intravenously 20 min before TPB)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 111

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam
Number of subjects: 111
Study: 1433582

Group type: EXPERIMENTAL
Intervention: Medical treatment (155 children)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Surgical treatment (151 children)
Number of subjects: 321
Study: 3912622

Group type: EXPERIMENTAL
Intervention: Chemo‐endocrine therapy (CMFp + T)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Endocrine therapy (p + T)
Number of subjects: 463

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 463
Study: 31004264

Group type: EXPERIMENTAL
Intervention: MindOut program
Number of subjects: 497
Study: 29291706

Group type: EXPERIMENTAL
Intervention: Multidisciplinary care program
Number of subjects: 263
Study: 24120032

Group type: EXPERIMENTAL
Intervention: Energy-restricted diet enriched in n-3 PUFAs (20 kcal/kg/ideal body weight/day, average 2.6 g/d)
Number of subjects: 44
Study: 23174637

Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Aggressive strategy
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 258
Study: 20626424

Group type: EXPERIMENTAL
Intervention: Flapless protocol with immediate loading (test)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional protocol with loading after 6 weeks (control)
Number of subjects: 14
Study: 17716943

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 3029

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 3029
Study: 15826234

Group type: EXPERIMENTAL
Intervention: CVC nonwords (e.g., pof)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCVC frame (e.g., grof)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CVCC frame (e.g., goft)
Number of subjects: 0
Study: 12505234

Group type: EXPERIMENTAL
Intervention: PAT-enhanced diagnosis
Number of subjects: 616

Group type: COMPARATOR
Intervention: ECG alone
Number of subjects: 616
Study: 9649987

Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 micrograms kg‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 micrograms kg‐1) + Clonidine (3 micrograms kg‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fentanyl alone (1.5 micrograms kg‐1)
Number of subjects: 12
Study: 8036288

Group type: EXPERIMENTAL
Intervention: Terbutaline inhaled by Turbuhaler (5 doses = 2.5 mg, t.i.d. for 2 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Terbutaline inhaled by Turbuhaler
Number of subjects: 40
Study: 2844076

Group type: EXPERIMENTAL
Intervention: Low-glycemic-index (GI) dinners
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-glycemic-index (GI) dinners
Number of subjects: 0
Study: 31691019

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg kg‐1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 13
Study: 29571930

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention with tailored text messages
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 29141611

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT-A) 200 units in paravertebral muscles
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 26325649

Group type: EXPERIMENTAL
Intervention: Occlusal splint combined with cognitive behavioral therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Occlusal splint alone
Number of subjects: 22
Study: 23973010

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 21511002

Group type: EXPERIMENTAL
Intervention: 6 mg of bromazepam
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14
Study: 18312043

Group type: EXPERIMENTAL
Intervention: Direct switch (DS)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Start-taper switch (STS)
Number of subjects: 368
Study: 17002053

Group type: EXPERIMENTAL
Intervention: Artificial pneumoperitoneum (PP) with chemotherapy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Chemotherapy only (Control)
Number of subjects: 138
Study: 14530471

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐WBC scintigraphy
Number of subjects: 313
Study: 10919343

Group type: EXPERIMENTAL
Intervention: Clamicin 500 mg (test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Biaxin 500 mg (reference formulation)
Number of subjects: 24
Study: 9208531

Group type: EXPERIMENTAL
Intervention: Qiwei Baizhu Powder (QWBZP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral Rehydration Solution (ORS)
Number of subjects: 60
Study: 1603294

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressant treatment (Imipramine)
Number of subjects: 0
Study: 4036778

Group type: EXPERIMENTAL
Intervention: Group type A behavior counseling for 9 months
Number of subjects: 118

Group type: COMPARATOR
Intervention: No counseling (Control)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Group type A behavior counseling
Number of subjects: 118
Study: 29553223

Group type: EXPERIMENTAL
Intervention: CAD-CAM insole
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Conventional insole
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sham insole
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: All groups (CAD-CAM, Conventional, Sham)
Number of subjects: 67
Study: 28858981

Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard treatment not specified)
Number of subjects: 0